|
1
|
Mazanet R and Antman KH: Sarcomas of soft
tissue and bone. Cancer. 68:463–473. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tawbi HA, Burgess M, Bolejack V, Van Tine
BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA,
et al: Pembrolizumab in advanced soft-tissue sarcoma and bone
sarcoma (SARC028): A multicentre, two-cohort, single-arm,
open-label, phase 2 trial. Lancet Oncol. 18:1493–1501. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shoushtari AN, Van Tine BA and Schwartz
GK: Novel treatment targets in sarcoma: More than just the GIST. Am
Soc Clin Oncol Educ Book. e488–e495. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saerens M, Brusselaers N, Rottey S,
Decruyenaere A, Creytens D and Lapeire L: Immune checkpoint
inhibitors in treatment of soft-tissue sarcoma: A systematic review
and meta-analysis. Eur J Cancer. 152:165–182. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Keung EZ, Lazar AJ, Torres KE, Wang WL,
Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird
J, et al: Phase II study of neoadjuvant checkpoint blockade in
patients with surgically resectable undifferentiated pleomorphic
sarcoma and dedifferentiated liposarcoma. BMC Cancer. 18:9132018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramachandran I, Lowther DE, Dryer-Minnerly
R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ,
Melchiori L, et al: Systemic and local immunity following adoptive
transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J
Immunother Cancer. 7:2762019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T,
Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, et al: Wilms'
tumor gene (WT1) competes with differentiation-inducing signal in
hematopoietic progenitor cells. Blood. 91:2969–2976. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sugiyama H: Cancer immunotherapy targeting
WT1 protein. Int J Hematol. 76:127–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oka Y, Tsuboi A, Kawakami M, Elisseeva OA,
Nakajima H, Udaka K, Kawase I, Oji Y and Sugiyama H: Development of
WT1 peptide cancer vaccine against hematopoietic malignancies and
solid cancers. Curr Med Chem. 13:2345–2352. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oji Y, Kitamura Y, Kamino E, Kitano A,
Sawabata N, Inoue M, Mori M, Nakatsuka S, Sakaguchi N, Miyazaki K,
et al: WT1 IgG antibody for early detection of nonsmall cell lung
cancer and as its prognostic factor. Int J Cancer. 125:381–387.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oji Y, Yamamoto H, Nomura M, Nakano Y,
Ikeba A, Nakatsuka S, Abeno S, Kiyotoh E, Jomgeow T, Sekimoto M, et
al: Overexpression of the Wilms' tumor gene WT1 in colorectal
adenocarcinoma. Cancer Sci. 94:712–717. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakatsuka S, Oji Y, Horiuchi T, Kanda T,
Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M,
et al: Immunohistochemical detection of WT1 protein in a variety of
cancer cells. Mod Pathol. 19:804–814. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugiyama H: Wilms' tumor gene WT1: Its
oncogenic function and clinical application. Int J Hematol.
73:177–187. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheever MA, Allison JP, Ferris AS, Finn
OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL,
Weiner LM and Matrisian LM: The prioritization of cancer antigens:
A national cancer institute pilot project for the acceleration of
translational research. Clin Cancer Res. 15:5323–5337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo
T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, et al:
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T
lymphocytes by WT1 peptide vaccine and the resultant cancer
regression. Proc Natl Acad Sci USA. 101:13885–13890. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Izumoto S, Tsuboi A, Oka Y, Suzuki T,
Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata
T, et al: Phase II clinical trial of Wilms tumor 1 peptide
vaccination for patients with recurrent glioblastoma multiforme. J
Neurosurg. 108:963–971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Keilholz U, Letsch A, Busse A, Asemissen
AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E and
Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms
tumor gene product 1 (WT1) peptide vaccination in patients with AML
and MDS. Blood. 113:6541–6548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oji Y, Oka Y, Nishida S, Tsuboi A,
Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita
M, et al: WT1 peptide vaccine induces reduction in minimal residual
disease in an imatinib-treated CML patient. Eur J Haematol.
85:358–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hashii Y, Sato-Miyashita E, Matsumura R,
Kusuki S, Yoshida H, Ohta H, Hosen N, Tsuboi A, Oji Y, Oka Y, et
al: WT1 peptide vaccination following allogeneic stem cell
transplantation in pediatric leukemic patients with high risk for
relapse: Successful maintenance of durable remission. Leukemia.
26:530–532. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maeda T, Hosen N, Fukushima K, Tsuboi A,
Morimoto S, Matsui T, Sata H, Fujita J, Hasegawa K, Nishida S, et
al: Maintenance of complete remission after allogeneic stem cell
transplantation in leukemia patients treated with Wilms tumor 1
peptide vaccine. Blood Cancer J. 3:e1302013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miyatake T, Ueda Y, Morimoto A, Enomoto T,
Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, et al: WT1
peptide immunotherapy for gynecologic malignancies resistant to
conventional therapies: A phase II trial. J Cancer Res Clin Oncol.
139:457–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oji Y, Inoue M, Takeda Y, Hosen N,
Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, et
al: WT1 peptide-based immunotherapy for advanced thymic epithelial
malignancies. Int J Cancer. 142:2375–2382. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishida S, Ishikawa T, Egawa S, Koido S,
Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Oba MS, et al:
Combination gemcitabine and WT1 peptide vaccination improves
progression-free survival in advanced pancreatic ductal
adenocarcinoma: A phase II randomized study. Cancer Immunol Res.
6:320–331. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maslak PG, Dao T, Bernal Y, Chanel SM,
Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila
ME, et al: Phase 2 trial of a multivalent WT1 peptide vaccine
(galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2:224–234.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yanagisawa R, Koizumi T, Koya T, Sano K,
Koido S, Nagai K, Kobayashi M, Okamoto M, Sugiyama H and Shimodaira
S: WT1-pulsed dendritic cell vaccine combined with chemotherapy for
resected pancreatic cancer in a phase I study. Anticancer Res.
38:2217–2225. 2018.PubMed/NCBI
|
|
26
|
Anguille S, Van de Velde AL, Smits EL, Van
Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van
Driessche A, et al: Dendritic cell vaccination as postremission
treatment to prevent or delay relapse in acute myeloid leukemia.
Blood. 130:1713–1721. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ochi T, Fujiwara H, Okamoto S, An J, Nagai
K, Shirakata T, Mineno J, Kuzushima K, Shiku H and Yasukawa M:
Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector
encoding silencers for endogenous TCRs shows marked antileukemia
reactivity and safety. Blood. 118:1495–1503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chapuis AG, Egan DN, Bar M, Schmitt TM,
McAfee MS, Paulson KG, Voillet V, Gottardo R, Ragnarsson GB,
Bleakley M, et al: T cell receptor gene therapy targeting WT1
prevents acute myeloid leukemia relapse post-transplant. Nat Med.
25:1064–1072. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oji Y, Hashimoto N, Tsuboi A, Murakami Y,
Iwai M, Kagawa N, Chiba Y, Izumoto S, Elisseeva O, Ichinohasama R,
et al: Association of WT1 IgG antibody against WT1 peptide with
prolonged survival in glioblastoma multiforme patients vaccinated
with WT1 peptide. Int J Cancer. 139:1391–1401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Petitprez F, de Reyniès A, Keung EZ, Chen
TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A,
et al: B cells are associated with survival and immunotherapy
response in sarcoma. Nature. 577:556–560. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schulz KF, Altman DG and Moher D; CONSORT
Group, : CONSORT 2010 Statement: Updated guidelines for reporting
parallel group randomised trials. BMJ. 340:c3322010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hayashi S, Imanishi R, Adachi M, Ikejima
S, Nakata J, Morimoto S, Fujiki F, Nishida S, Tsuboi A, Hosen N, et
al: Reader-free ELISPOT assay for immuno-monitoring in
peptide-based cancer vaccine immunotherapy. Biomed Rep. 12:244–250.
2020.PubMed/NCBI
|
|
35
|
Fujiki F, Oka Y, Tsuboi A, Kawakami M,
Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, et
al: Identification and characterization of a WT1 (Wilms Tumor Gene)
protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that
promotes the induction and activation of WT1-specific cytotoxic T
lymphocytes. J Immunother. 30:282–293. 2007.PubMed/NCBI
|
|
36
|
Ueda T, Oji Y, Naka N, Nakano Y, Takahashi
E, Koga S, Asada M, Ikeba A, Nakatsuka S, Abeno S, et al:
Overexpression of the Wilms' tumor gene WT1 in human bone and
soft-tissue sarcomas. Cancer Sci. 94:271–276. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sotobori T, Ueda T, Oji Y, Naka N, Araki
N, Myoui A, Sugiyama H and Yoshikawa H: Prognostic significance of
Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma.
Cancer. 106:2233–2240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oue T, Uehara S, Yamanaka H, Takama Y, Oji
Y and Fukuzawa M: Expression of Wilms tumor 1 gene in a variety of
pediatric tumors. J Pediatr Surg. 46:2233–2238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Merchant MS, Wright M, Baird K, Wexler LH,
Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R,
Wolchok JD, et al: Phase I clinical trial of ipilimumab in
pediatric patients with advanced solid tumors. Clin Cancer Res.
22:1364–1370. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thanindratarn P, Dean DC, Nelson SD,
Hornicek FJ and Duan Z: Advances in immune checkpoint inhibitors
for bone sarcoma therapy. J Bone Oncol. 15:1002212019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsuboi A, Hashimoto N, Fujiki F, Morimoto
S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, et
al: A phase I clinical study of a cocktail vaccine of Wilms' tumor
1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Cancer Immunol Immunother. 68:331–340. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Foulds KE, Rotte MJ and Seder RA: IL-10 is
required for optimal CD8 T cell memory following Listeria
monocytogenes infection. J Immunol. 177:2565–2574. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Giovarelli M, Musiani P, Modesti A,
Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, di
Pierro F, De Giovanni C, et al: Local release of IL-10 by
transfected mouse mammary adenocarcinoma cells does not suppress
but enhances antitumor reaction and elicits a strong cytotoxic
lymphocyte and antibody-dependent immune memory. J Immunol.
155:3112–3123. 1995.PubMed/NCBI
|
|
44
|
Petersson M, Charo J, Salazar-Onfray F,
Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T and Kiessling R:
Constitutive IL-10 production accounts for the high NK sensitivity,
low MHC class I expression, and poor transporter associated with
antigen processing (TAP)-1/2 function in the prototype NK target
YAC-1. J Immunol. 161:2099–2105. 1998.PubMed/NCBI
|
|
45
|
Fujiki F, Oka Y, Kawakatsu M, Tsuboi A,
Tanaka-Harada Y, Hosen N, Nishida S, Shirakata T, Nakajima H,
Tatsumi N, et al: A clear correlation between WT1-specific Th
response and clinical response in WT1 CTL epitope vaccination.
Anticancer Res. 30:2247–2254. 2010.PubMed/NCBI
|
|
46
|
McKay K, Moore PC, Smoller BR and Hiatt
KM: Association between natural killer cells and regression in
melanocytic lesions. Hum Pathol. 42:1960–1964. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Blass E and Ott PA: Advances in the
development of personalized neoantigen-based therapeutic cancer
vaccines. Nat Rev Clin Oncol. 18:215–229. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Largeot A, Pagano G, Gonder S, Moussay E
and Paggetti J: The B-side of cancer immunity: The underrated tune.
Cells. 8:4492019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sarvaria A, Madrigal JA and Saudemont A: B
cell regulation in cancer and anti-tumor immunity. Cell Mol
Immunol. 14:662–674. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tao H, Lu L, Xia Y, Dai F, Wang Y, Bao Y,
Lundy SK, Ito F, Pan Q, Zhang X, et al: Antitumor effector B cells
directly kill tumor cells via the Fas/FasL pathway and are
regulated by IL-10. Eur J Immunol. 45:999–1009. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Olkhanud PB, Damdinsuren B, Bodogai M,
Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP and Biragyn A:
Tumor-evoked regulatory B cells promote breast cancer metastasis by
converting resting CD4+ T cells to T-regulatory cells.
Cancer Res. 71:3505–3515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pylayeva-Gupta Y, Das S, Handler JS, Hajdu
CH, Coffre M, Koralov SB and Bar-Sagi D: IL35-producing B cells
promote the development of pancreatic neoplasia. Cancer Discov.
6:247–255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Schwartz M, Zhang Y and Rosenblatt JD: B
cell regulation of the anti-tumor response and role in
carcinogenesis. J Immunother Cancer. 4:402016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Moeller I, Spagnoli GC, Finke J, Veelken H
and Houet L: Uptake routes of tumor-antigen MAGE-A3 by dendritic
cells determine priming of naive T-cell subtypes. Cancer Immunol
Immunother. 61:2079–2090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Roumenina LT, Daugan MV, Petitprez F,
Sautes-Fridman C and Fridman WH: Context-dependent roles of
complement in cancer. Nat Rev Cancer. 19:698–715. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu J, Wang Y, Xiong E, Hong R, Lu Q, Ohno
H and Wang JY: Role of the IgM Fc receptor in immunity and
tolerance. Front Immunol. 10:5292019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kubagawa H, Oka S, Kubagawa Y, Torii I,
Takayama E, Kang DW, Gartland GL, Bertoli LF, Mori H, Takatsu H, et
al: Identity of the elusive IgM Fc receptor (FcmuR) in humans. J
Exp Med. 206:2779–2793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ouchida R, Mori H, Hase K, Takatsu H,
Kurosaki T, Tokuhisa T, Ohno H and Wang JY: Critical role of the
IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral
immune responses. Proc Natl Acad Sci USA. 109:E2699–E2706. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ouchida R, Lu Q, Liu J, Li Y, Chu Y,
Tsubata T and Wang JY: FcµR interacts and cooperates with the B
cell receptor To promote B cell survival. J Immunol. 194:3096–3101.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Honjo K, Kubagawa Y, Suzuki Y, Takagi M,
Ohno H, Bucy RP, Izui S and Kubagawa H: Enhanced auto-antibody
production and Mott cell formation in FcµR-deficient autoimmune
mice. Int Immunol. 26:659–672. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yu J, Duong VHH, Westphal K, Westphal A,
Suwandi A, Grassl GA, Brand K, Chan AC, Föger N and Lee KH: Surface
receptor Toso controls B cell-mediated regulation of T cell
immunity. J Clin Invest. 128:1820–1836. 2018. View Article : Google Scholar : PubMed/NCBI
|
